The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.
Quiz|Articles|May 1, 2026
OncLive Weekly News Quiz (5/1/2026): Are You Caught Up on 2 FDA ODAC Votes in Prostate and Breast Cancer?
Author(s)OncLive Staff
Fact checked by: Chris Ryan
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
How did the FDA’s Oncologic Drugs Advisory Committee (ODAC) vote on capivasertib (Truqap) plus abiraterone acetate (Zytiga) based on findings from the phase 3 CAPItello-281 trial (NCT04493853) in PTEN-deficient metastatic hormone-sensitive prostate cancer; and on switching to camizestrant based data from the phase 3 SERENA-6 trial (NCT04964934) in ESR1-mutant, hormone receptor–positive metastatic breast cancer?
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Patrick Forde, MD, MBBCh, details how chemoimmunotherapy, pathologic response, and targeted therapy are reshaping resectable NSCLC care.
The filing is supported by phase 3 REZILIENT3 data showing a median PFS of 14.5 vs 8.5 months with zipalertinib plus chemotherapy vs chemotherapy.
Phase 2 Co-PSMA data showed higher lesion detection with 64Cu-SAR-bisPSMA vs 68Ga-PSMA-11 in biochemical recurrence after prostatectomy.
Check out this October recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.
Check out this October recap of OncLive’s coverage of the top news and expert insights in breast cancer.
Experts weigh genomic testing, treatment intensification, and radioligand sequencing in advanced prostate cancer care.
Advertisement
Advertisement
Trending on OncLive
1
Cardiovascular and Bleeding Risk With BTK Inhibitors in CLL
2
FDA Approves Durvalumab Plus Enfortumab Vedotin for Cisplatin-Ineligible MIBC
3
CHMP Recommends Approval of Belzutifan Plus Lenvatinib for Advanced ccRCC After PD-(L)1 Inhibition
4
Expanding Clinical Trial Access Through Community Oncology
5